Capstone Investment Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$427K Sell
6,800
-2,400
-26% -$167K ﹤0.01% 1218
2025
Q4
$611K Sell
9,200
-5,100
-36% -$330K ﹤0.01% 1074
2025
Q3
$962K Sell
14,300
-4,500
-24% -$356K ﹤0.01% 1049
2025
Q2
$1.64M Buy
18,800
+7,600
+68% +$596K ﹤0.01% 708
2025
Q1
$765K Sell
11,200
-67,900
-86% -$5.54M ﹤0.01% 959
2024
Q4
$6.15M Buy
79,100
+52,700
+200% +$3.9M 0.01% 474
2024
Q3
$1.77M Buy
26,400
+500
+2% +$41.1K 0.01% 775
2024
Q2
$2.94M Buy
25,900
+12,300
+90% +$1.56M 0.01% 603
2024
Q1
$1.89M Sell
13,600
-10,200
-43% -$1.28M 0.01% 809
2023
Q4
$2.95M Buy
23,800
+12,300
+107% +$1.26M 0.01% 692
2023
Q3
$1.07M Buy
11,500
+1,300
+13% +$147K ﹤0.01% 958
2023
Q2
$1.31M Buy
10,200
+500
+5% +$60.5K 0.01% 768
2023
Q1
$1.13M Buy
9,700
+2,100
+28% +$235K 0.01% 756
2022
Q4
$861K Buy
7,600
+2,100
+38% +$231K 0.01% 981
2022
Q3
$443K Sell
5,500
-15,400
-74% -$1.3M ﹤0.01% 1313
2022
Q2
$1.56M Sell
20,900
-7,100
-25% -$648K 0.01% 855
2022
Q1
$3.58M Sell
28,000
-25,200
-47% -$2.76M 0.01% 817
2021
Q4
$7.14M Sell
53,200
-400
-0.7% -$57.5K 0.01% 720
2021
Q3
$7.33M Sell
53,600
-400
-0.7% -$50.4K 0.01% 722
2021
Q2
$5.76M Buy
54,000
+5,200
+11% +$499K 0.01% 691
2021
Q1
$4.38M Buy
48,800
+21,200
+77% +$1.99M 0.01% 684
2020
Q4
$2.55M Buy
27,600
+1,600
+6% +$143K 0.01% 804
2020
Q3
$2.68M Buy
26,000
+2,400
+10% +$251K 0.01% 716
2020
Q2
$2.39M Buy
+23,600
New +$2.11M 0.02% 654

Other funds holding DXCM

Capstone Investment Advisors's DXCM Position: Q1 2026 in Review

Capstone Investment Advisors increased its DexCom (DXCM) stake by 5.5% in Q1 2026, buying an estimated $198K and bringing the position to 54,715 shares worth $3.44M. The position accounts for 0.01% of the portfolio, ranked #504.

Capstone Investment Advisors first reported a position in DXCM in Q4 2020 and has held it in 16 quarters since. The position peaked at $8.04M in Q3 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Capstone Investment Advisors held 54,715 shares of DexCom worth $3.44M as of Q1 2026.
  • Capstone Investment Advisors bought 2,840 DexCom shares in Q1 2026, an estimated $198K.
  • DexCom made up 0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #504 holding.
  • Capstone Investment Advisors first reported a position in DexCom in Q4 2020 and has held it in 16 quarters since.
  • Capstone Investment Advisors's DexCom position peaked at $8.04M in Q3 2025.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.